Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis.

Miyazaki, Tatsuya; Kohno, Shigeru; Kaku, Mitsuo; Koga, Hironobu; Yamaguchi, Keizo

doi:10.1620/tjem.161.273

Cited by 13 publications

(9 citation statements)

References 8 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…liposome ; amphotericin B ; amylopectin ; pulmonary candidiasis ; HPLC Encapsulation of amphotericin B with liposomes decreases its toxicity (Graybill et al 1982;Lopez-Berestein et al 1984b). We also confirmed reduced toxicity and increased efficacy of liposomal amphotericin B in murine candidiasis (Miyazaki et al 1990). Liposomes distribute mainly in the reticuloendothelial systems, but coating liposomes with polysaccharide reduced the distribution.…”

supporting

confidence: 69%

“…One hundred percent of the drug was incorporated in liposomes in our study (data not shown). We previously reported that encapsulation with liposomes enhanced the efficacy of amphotericin B in the treatment of murine candidiasis, due to decreased toxicity (Miyazaki et al 1990). In this study, amphotericin B encapsulated in amylopectin-coated liposomes showed better efficacy than conventional liposomes for the treatment of murine pulmonary candidiasis.…”

Section: Discussionmentioning

confidence: 99%

“…The lungs, liver, spleen, heart, brain, and kidneys were removed and homogenized with 1.0 ml of sterile saline, and then serial dilutions were made to count the number of Candida albicans in organs (Miyazaki et al 1990). …”

Section: Number Of Candida Albicans In Organsmentioning

confidence: 99%

See 2 more Smart Citations

Polysaccharide-Coated Liposomal Amphotericin B for the Treatment of Murine Pulmonary Candidiasis.

Miyazaki

Kohno

Sasayama

et al. 1992

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

M., SATO, T. and SUNAMOTO, J. Polysaccharide-Coated Liposomal Amphotericin B for the Treatment of Murine Pulmonary Candidiasis. Tohoku J. Exp. Med., 1992, 168 (3), [483][484][485][486][487][488][489][490] Amylopectin-coated liposomal amphotericin B was investigated in a murine model of pulmonary candidiasis. The LD50 of amylopectincoated liposomal amphotericin B in normal mice was more than 10.0 mg/kg, and that of conventional amphotericin B was 1.2 mg/kg. Amylopectin-coated liposomes showed twice the concentration in the lungs of conventional liposomes. Candida albicans was inoculated intratracheally into BALB/C mice. Twentyfour hours later, the number of Candida in the lungs of mice treated with amylopectin-coated liposomes was less than in those treated with conventional liposomes, and amylopectin-coated liposomes improved the survival rate of inoculated mice. Coating liposomes with amylopectin aids the targeting of amphotericin B to the lungs. liposome ; amphotericin B ; amylopectin ; pulmonary candidiasis ; HPLC Encapsulation of amphotericin B with liposomes decreases its toxicity (Graybill et al. 1982;Lopez-Berestein et al. 1984b). We also confirmed reduced toxicity and increased efficacy of liposomal amphotericin B in murine candidiasis (Miyazaki et al. 1990). Liposomes distribute mainly in the reticuloendothelial systems, but coating liposomes with polysaccharide reduced the distribution. Takada and co-workers reported that polysaccharide-coated liposomes distributed more preferentially in the lungs than conventional liposomes (Takada et al. 1984). In the present study, the higher concentrations of polysaccharide-coated liposomes in lungs suggested their therapeutic efficacy in respiratory infection. We used these polysaccharide-coated liposomes as an amphotericin B carrier for the therapy of murine pulmonary candidiasis.

show abstract

supporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Polysaccharide-Coated Liposomal Amphotericin B for the Treatment of Murine Pulmonary Candidiasis.

Miyazaki

Kohno

Sasayama

et al. 1992

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Twenty-microliter quantities of rabbit serum and 20 p 1 of anti-candida antibody coated latex were mixed on glass slides. The numbers of viable fungi in the right kidney were counted and histological examination of the left kidney was also performed (Miyazaki et al 1990). …”

Section: Experimental Candidiasis In Rabbitsmentioning

confidence: 99%

Combination of Conventional and Endotoxin-Specific Limulus Tests for Measurement of Polysaccharides in Sera of Rabbits with Experimental Systemic Candidiasis.

Miyazaki

Kohno

Mitsutake

et al. 1992

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

“…We utilized a leucopenic mouse model of disseminated candidiasis to correlate PK/PD parameters for AmBisome with in vivo antifungal efficacy, as assessed by the fungal burden in the kidney, demonstrated as the most infected organ in this infection model (12,16). Before this investigation, the timing of the start of treatment was decided in consideration of the time course of the viable cell count in the blood and kidney.…”

mentioning

confidence: 99%

Evaluation of Antifungal Pharmacodynamic Characteristics of AmBisome against Candida albicans

Koji

Yamamoto

Ueda

2006

Microbiology and Immunology

View full text Add to dashboard Cite

Amphotericin B (AMB) has been historically considered the 'gold standard' therapy for systemic fungal infections (14). In a pharmacodynamic profile, AMB exhibits concentration-dependent antifungal activity (4,11). On the other hand, AMB has a wide variety of acute and chronic side effects, and in particular, dosedependent nephrotoxicity has limited its use (8). Thus, the therapeutic dose is often determined by renal tolerance rather than infection severity.To reduce AMB toxicity, a liposomal formulation of AMB (AmBisome), comprising small unilamellar vesicles containing the AMB molecule, has been developed. As a consequence of AMB integration into the hydrophobic membrane, AmBisome exhibits characteristic pharmacokinetics of a liposome, and has pharmacological profiles and toxic properties different from those of AMB (1, 2, 5, 6). Although AmBisome possesses an antifungal activity, it is not clear whether it exhibits the same pharmacodynamic properties as AMB. Therefore, in this study, we conducted a timekill curve study with AmBisome and AMB deoxycholate (Fungizone) against Candida albicans in an effort to characterize the relationship between the concentration and in vitro antifungal activity, and characterized the pharmacokinetic/pharmacodynamic (PK/PD) parameter predictive of the in vivo efficacy of AmBisome in a leucopenic mouse model of disseminated candidiasis. Materials and Methods

show abstract

Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis.

Cited by 13 publications

References 8 publications

Polysaccharide-Coated Liposomal Amphotericin B for the Treatment of Murine Pulmonary Candidiasis.

Polysaccharide-Coated Liposomal Amphotericin B for the Treatment of Murine Pulmonary Candidiasis.

Combination of Conventional and Endotoxin-Specific Limulus Tests for Measurement of Polysaccharides in Sera of Rabbits with Experimental Systemic Candidiasis.

Evaluation of Antifungal Pharmacodynamic Characteristics of AmBisome against Candida albicans

Contact Info

Product

Resources

About